Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA + parafascicular lesions

Brain Research Bulletin

Volumn 78, Issue 2-3, 2009, Pages 91-96

  Truong, L ^a   Allbutt, H N ^a   Coster, M J ^b   Kassiou, M ^b,c   Henderson, J M ^a  

^a Institute for Biomedical Research   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

6 Hydroxydopamine; Centromedian parafascicular complex; l dopa; NMDA antagonist; Parkinson's disease; Rat behavioural analysis

Indexed keywords

LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2 ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR NR1A ANTAGONIST; OXIDOPAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; BRAIN REGION; CONTROLLED STUDY; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; THALAMUS PARAFASCICULAR NUCLEUS;

ADMINISTRATION, ORAL; ADRENERGIC AGENTS; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; IMMUNOHISTOCHEMISTRY; INTRALAMINAR THALAMIC NUCLEI; LEVODOPA; MEDIAL FOREBRAIN BUNDLE; N-METHYLASPARTATE; NEURONS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; POSTURAL BALANCE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; ROTATION; TYROSINE 3-MONOOXYGENASE;

EID: 58749111290     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2008.10.004     Document Type: Article

References (19)

1. Allbutt H.N., and Henderson J.M. Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease. J. Neurosci. Methods 159 (2007) 195-202
2. Aymerich M.S., Barroso-Chinea P., Perez-Manso M., Munoz-Patino A.M., Moreno-Igoa M., Gonzalez-Hernandez T., and Lanciego J.L. Consequences of unilateral nigrostriatal denervation on the thalamostriatal pathway in rats. Eur. J. Neurosci. 23 (2006) 2099-2108
3. Bacci J.J., Kachidian P., Kerkerian-Le Goff L., and Salin P. Intralaminar thalamic nuclei lesions: widespread impact on dopamine denervation-mediated cellular defects in the rat basal ganglia. J. Neuropathol. Exp. Neurol. 63 (2004) 20-31
4. Calon F., Rajput A.H., Hornykiewicz O., Bedard P.J., and Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis. 14 (2003) 404-416
5. Claiborne C.F., McCauley J.A., Libby B.E., Curtis N.R., Diggle H.J., Kulagowski J.J., Michelson S.R., Anderson K.D., Claremon D.A., Freidinger R.M., Bednar R.A., Mosser S.D., Gaul S.L., Connolly T.M., Condra C.L., Bednar B., Stump G.L., Lynch J.J., Macaulay A., Wafford K.A., Koblan K.S., and Liverton N.J. Orally efficacious NR2B-selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. 13 (2003) 697-700
6. Freyaldenhoven T.E., Ali S.F., and Schmued L.C. Systemic administration of MPTP induced thalamic neuronal degeneration in mice. Brain Res. 759 (1997) 9-17
7. Ghorayeb I., Fernagut P.O., Hervier L., Labattu B., Bioulac B., and Tison F. A 'single toxin-double lesion' rat model of striatonigral degeneration by intrastriatal 1-methyl-4-phenylpyridinium ion injection: a motor behavioural analysis. Neuroscience 115 (2002) 533-546
8. Henderson J.M., Carpenter K., Cartwright H., and Halliday G.M. Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann. Neurol. 47 (2000) 345-352
9. Henderson J.M., Schleimer S.B., Allbutt H.N., Dabholkar V., Abela D., Jovic J., and Quinlivan M. Behavioural effects of parafascicular thalamic lesions in an animal model of parkinsonism. Behav. Brain Res. 162 (2005) 222-232
10. Lanciego J.L., Gonzalo N., Castle M., Sanchez-Escobar C., Aymerich M.S., and Obeso J.A. Thalamic innervation of striatal and subthalamic neurons projecting to the rat entopeduncular nucleus. Eur. J. Neurosci. 19 (2004) 1267-1277
11. Leaver K.R., Allbutt H.N., Creber N.J., Kassiou M., and Henderson J.M. Neuroprotective effects of a selective N-methyl-d-aspartate NR2B receptor antagonist in the 6-OHDA rat model of Parkinson's disease. Clin Exp Pharmacol Physiol. 35 (2008 Nov) 1388-1394
12. Loschmann P.A., De Groote C., Smith L., Wullner U., Fischer G., Kemp J.A., Jenner P., and Klockgether T. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp. Neurol. 187 (2004) 86-93
13. Nash J.E., Ravenscroft P., McGuire S., Crossman A.R., Menniti F.S., and Brotchie J.M. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates l-dopa-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of l-dopa in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 188 (2004) 471-479
14. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd ed. (1997), Academic Press, New York
15. Sidibe M., Pare J.F., and Smith Y. Nigral and pallidal inputs to functionally segregated thalamostriatal neurons in the centromedian/parafascicular intralaminar nuclear complex in monkey. J. Comp. Neurol. 447 (2002) 286-299
16. Smith Y., Raju D.V., Pare J.F., and Sidibe M. The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci. 27 (2004) 520-527
17. Steece-Collier K., Chambers L.K., Jaw-Tsai S.S., Menniti F.S., and Greenamyre J.T. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp. Neurol. 163 (2000) 239-243
18. Warraich S.T., Allbutt H.N., Billing R., Radford J., Kassiou M., and Henderson J.M. Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesioned rat. Brain Res. Bull. 78 (2009) 85-90
19. Wessell R.H., Ahmed S.M., Menniti F.S., Dunbar G.L., Chase T.N., and Oh J.D. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology 47 (2004) 184-194